Articles

Results of a phase 3 study of an investigational monoclonal antibody, MABp1 (Xilonix; XBiotech), evaluated for cachexia in metastatic colorectal cancer (CRC), revealed a surprising finding: patients in the experimental arm showed a trend toward increased overall survival (an end point difficult to reach in any treatment-refractory cancer), with pharmacodynamics activity consistent with this result, investigators reported at the 2015 Gastrointestinal Cancers Symposium, held in San Francisco, CA. Read More ›

Cancer survivors with chronic diseases are falling through the cracks, said Sarah Scarpace, PharmD, MPH, BCOP, at the 11th annual Hematology/Oncology Pharmacy Association conference. When oncologists are no longer managing chronic diseases like diabetes and hypertension, a window of opportunity exists for pharmacists to become involved in multidisciplinary cancer survivorship team models. Read More ›

A January 14, 2015, report published by the Institute of Medicine (IOM) walks a fine line between the competing clinical data-sharing comfort zones of pharmaceutical companies, physician associations, patient groups, and other advocacy organizations. Read More ›

Among the various types of treatment that a patient with cancer may undergo, chemotherapy is associated with the greatest concerns with respect to side effects. Although patients may comprehend the importance of receiving chemotherapy as a key component of their treatment plan, the fear of adverse events (AEs) is always foremost on their minds. Read More ›

It is inevitable that patients with cancer will experience some side effects associated with treatment. Recommendations for managing and minimizing these complications are critical to patients’ well-being and can impact overall clinical outcomes. Read More ›

As an oncology pharmacist in an ambulatory cancer clinic, in the course of a typical week, it is not unusual for me to counsel 25 to 30 new patients on chemotherapy regimens that they are about to receive (paying particular attention to adverse events [AEs]), and to be directly involved in the monitoring and management of countless other patients who present with side effects associated with their treatments. Read More ›

In its eighth year, The Oncology Pharmacist (TOP) will continue to provide oncology pharmacists and their colleagues with the latest research findings and results of large clinical trials, interviews with thought leaders, as well as content for pharmacy students and residents, and articles on practice management. Read More ›

St. Joseph’s/Candler Health System was established through a joint operating agreement between 2 religious institutions—St. Joseph’s, a Catholic hospital, and Candler, a Methodist hospital. It is the only faith-based healthcare system in southeast Georgia. Read More ›